https://www.globenewswire.com/en/news-release/2026/04/14/3273005/0/en/PannTheraPi-Announces-Significant-Clinical-Development-and-Strategic-Milestones.html
Panntherapi annonces:
- Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and severe form of epilepsy
- European patent covering the use of its drug candidate in epilepsy is now granted
- Sophie Binay is appointed as General Manager and Chief Scientific Officer